QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
1/3 of new medicines are not available to Swedish patients
Quantify Research has supported the Swedish Association of the Pharmaceutical Industry (LIF) to re-analyse the EFPIA 2017 Patients W.A.I.T. Indicator for new medicines. We found that about 1/3 of EMA approved medicines are not available in Sweden. Some of these can be replaced with other treatment options, but in other cases Swedish patients may suffer consequences from not having access to the latest medicines available for their disease. For […]
Quantify attended meeting on priority outcomes in Alzheimer’s disease (the IMI ROADMAP project)
On June 11th Anders Gustavsson attended a productive meeting at Edinburgh University on priority outcomes in Alzheimer’s disease. This effort is part of the IMI ROADMAP project aiming to improve the use of RWE in Alzheimer’s disease.
Visit the ROADMAP website for more info.
ISPOR’s HTA Resource Center – a collection of useful tools and resources
Looking for tools and resources to support and inform HTA? Quantify recommends ISPOR’s HTA Resource Center – a previously available website which has been updated to allow for easier access to key HTA articles, guidance as well as upcoming conferences, HTA training events, and more.
Useful Health Economics links, including blogs and resources (updated April 2018)
We have compiled a list of useful blogs and resources, which may help you stay on top of the evolving world of health economics and outcomes research. It’s by no means a complete list, we will be adding interesting new sites continuously. We hope you find this helpful.
Blogs:
https://aheblog.com/ – Blog with several contributors covering many aspects of health economics, including weekly journal update.
[…]